A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer

Principal investigator: Peeter Karihtala
Trial site: HUS Comprehensive Cancer Center

Link to the ClinicalTrials.gov study website